MiR-221 Facilitates the TGFbeta1-induced Epithelial-mesenchymal Transition in Human Bladder Cancer Cells by Targeting STMN1

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2015 May 1

PMID 25928257

Citations 23

Authors

Jun Liu

Jian Cao

Xiaokun Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Distant metastasis is the major cause of cancer-related death, and epithelial-to-mesenchymal transition (EMT) has a critical role in this process. Accumulating evidence indicates that EMT can be regulated by microRNAs (miRNAs). miR-221, as oncogenes in several human cancers, was significantly up-regulated in bladder cancers. However, the role of miR-221 in the progression of bladder cancer metastasis remains largely unknown.

Methods: We used qRT-PCR and western blot to accurately measure the levels of miR-221, STMN1 and EMT markers in TGFβ1 induced EMT of bladder cancer cells. miR-221 inhibitors were re-introduced into bladder cancer cells to investigate its role on tumor metastasis which was measured by MTT, wound healing, transwell invasion and adherent assays. Luciferase reporter assay was used to reveal the target gene of miR-221.

Results: miR-221 expression was greatly increased by TGFβ1 in bladder cancer cell. miR-221 inhibition reversed TGFβ1 induced EMT by sharply increasing the expression of the epithelial marker E-cadherin and decreasing the expression of the mesenchymal markers vimentin, Fibroactin and N-cadherin. Furthermore, miR-221 expression is positively correlated with malignant potential of bladder cancer cell through promoting loss of cell adhesion and prometastatic behavior. Luciferase reporter assay revealed that miR-221 negatively regulates STMN1 expression by direct targeting to the 3'UTR region of STMN1.

Conclusions: Our study demonstrated that miR-221 facilitated TGFβ1-induced EMT in human bladder cancer cells by targeting STMN1 and represented a promising therapeutic target in the process of metastasis.

Citing Articles

Soloxolone -methylanilide effectively suppresses aggressive phenotype of glioblastoma cells including TGF-β1-induced glial-mesenchymal transition and inhibits growth of U87 glioblastoma xenografts in mice.

Odarenko K, Senkova A, Salomatina O, Markov O, Salakhutdinov N, Zenkova M Front Pharmacol. 2024; 15:1428924.

PMID: 39135794 PMC: 11317440. DOI: 10.3389/fphar.2024.1428924.

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.

Ungefroren H, Kunstner A, Busch H, Franzenburg S, Luley K, Viol F Int J Mol Sci. 2022; 23(24).

PMID: 36555512 PMC: 9781720. DOI: 10.3390/ijms232415868.

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.

Di Martino M, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K Mol Ther Nucleic Acids. 2022; 27:1191-1224.

PMID: 35282417 PMC: 8891816. DOI: 10.1016/j.omtn.2022.02.005.

Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer.

Benjamin D, Lyou Y Cancers (Basel). 2021; 13(22).

PMID: 34830879 PMC: 8616345. DOI: 10.3390/cancers13225724.

regulated diabetic retinal epithelial-mesenchymal transition through regulating miR-204/SOX4 axis.

Yang Y, Zhou J, Li W, Zhou Z, Xia X PeerJ. 2021; 9:e11817.

PMID: 34386303 PMC: 8312494. DOI: 10.7717/peerj.11817.

References

Baldassarre G, Belletti B, Nicoloso M, Schiappacassi M, Vecchione A, Spessotto P . p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 2005; 7(1):51-63. DOI: 10.1016/j.ccr.2004.11.025. View

Zavadil J, Bottinger E . TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24(37):5764-74. DOI: 10.1038/sj.onc.1208927. View

Huber M, Kraut N, Beug H . Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17(5):548-58. DOI: 10.1016/j.ceb.2005.08.001. View

Levy L, Hill C . Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2005; 17(1-2):41-58. DOI: 10.1016/j.cytogfr.2005.09.009. View

Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi J . MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007; 104(9):3432-7. PMC: 1805579. DOI: 10.1073/pnas.0611192104. View

Liang C, Park A, Guan J . In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2(2):329-33. DOI: 10.1038/nprot.2007.30. View

Gottardo F, Liu C, Ferracin M, Calin G, Fassan M, Bassi P . Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007; 25(5):387-92. DOI: 10.1016/j.urolonc.2007.01.019. View

Gregory P, Bert A, Paterson E, Barry S, Tsykin A, Farshid G . The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10(5):593-601. DOI: 10.1038/ncb1722. View

Rana S, Maples P, Senzer N, Nemunaitis J . Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008; 8(9):1461-70. DOI: 10.1586/14737140.8.9.1461. View

10.

Parkin D . The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008; (218):12-20. DOI: 10.1080/03008880802285032. View

11.

Creighton C, Chang J, Rosen J . Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15(2):253-60. DOI: 10.1007/s10911-010-9173-1. View

12.

Lu Q, Lu C, Zhou G, Zhang W, Xiao H, Wang X . MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol. 2009; 28(6):635-41. DOI: 10.1016/j.urolonc.2009.06.005. View

13.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

14.

Nauseef J, Henry M . Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?. Nat Rev Urol. 2011; 8(8):428-39. PMC: 6858788. DOI: 10.1038/nrurol.2011.85. View

15.

Stinson S, Lackner M, Adai A, Yu N, Kim H, OBrien C . miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011; 4(186):pt5. DOI: 10.1126/scisignal.2002258. View

16.

Nemunaitis J . Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 2012; 16(7):631-4. DOI: 10.1517/14728222.2012.696101. View

17.

Williams K, Ghosh R, Giridhar P, Gu G, Case T, Belcher S . Inhibition of stathmin1 accelerates the metastatic process. Cancer Res. 2012; 72(20):5407-17. PMC: 3543831. DOI: 10.1158/0008-5472.CAN-12-1158. View

18.

Hwang M, Yu N, Stinson S, Yue P, Newman R, Allan B . miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 2013; 8(6):e66502. PMC: 3679042. DOI: 10.1371/journal.pone.0066502. View

19.

Ha G, Kim J, Breuer E, Breuer E . TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One. 2013; 8(8):e70353. PMC: 3731346. DOI: 10.1371/journal.pone.0070353. View

20.

Liu B, Che W, Xue J, Zheng C, Tang K, Zhang J . SIRT4 prevents hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Cell Physiol Biochem. 2013; 32(3):655-62. DOI: 10.1159/000354469. View